1. Generics Bulletin
  2. >>Leadership

Who’s Hired? New Mithra CEO Mulls Selling Generics Business

As Sawai Reorganizes Management And Coury Steps Down As Viatris Chair

 
• By Dave Wallace

Mithra’s new CEO has immediately signaled a potential sale for the firm’s generics business as it looks to focus on branded assets in women’s health. Meanwhile, Sawai has reorganized its management team, the longtime chair of Viatris is moving on to another role, and a former AAM vice-president has joined Sandoz.

Sell decision - yes or no? - with wooden blocks
Mithra’s new CEO is considering selling its generics business • Source: Shutterstock

Just over a month into the position, Mithra’s new CEO David Solomon has signaled plans to potentially sell the firm’s generics business as it looks to focus on its branded assets in women’s health.

In a letter to shareholders, Solomon – who took over as Mithra CEO from Leon Van Rompay on 11 April – said that while the generics business “holds value and could serve to diversify our portfolio of products in the long-run, it is a low-margin business that can act as a brake on growth while also

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

More from Generics Bulletin

Cutting Out The Middlemen? Trump’s Pricing Order Offers Opportunity On PBMs

 
• By Dave Wallace

Donald Trump’s executive order on most-favored-nation prescription drug pricing could provide positive opportunities for the off-patent industry, although US generics and biosimilars association the AAM suggested that the administration might do more good by focusing elsewhere.

Pfizer Discusses Tariffs Amid International Slump For Oncology Biosimilars Revenue

 
• By Adam Zamecnik

Reflecting conversations across the wider pharmaceutical industry, Pfizer’s earnings call for the first quarter of 2025 focused on the sector’s response to the potential imposition of tariffs by the Trump administration.

Amneal Proud To Be ‘Made In America’ And Ready To Scale Up Its US Manufacturing

 
• By Urtė Fultinavičiūtė

Amneal has set itself apart from competitors who are scrambling to find alternatives if proposed US pharmaceutical tariffs come into place. For the New Jersey-based firm, this is an opportunity to embrace its American identity and open a new chapter of growth.